ArticleNature metabolism2020
T1D progression is associated with loss of CD3
Article in Nature metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Efficiency of bone marrow-derived cells in the treatment of experimental autoimmune type 1 diabetes: immunomodulatory and anti-apoptotic properties.BMC immunology · 2026Article
- Imbalance of stem-like and effector T cell states in children with early type 1 diabetes across conventional and regulatory subsets.Nature communications · 2025Article
- Sex-based immunological differences in multisystem inflammatory syndrome in children: potential role of TFrontiers in immunology · 2025Article
- Article
- TInternational journal of molecular sciences · 2024Article
- Immune Profile in COVID-19: Unveiling TInternational journal of molecular sciences · 2024Article
- Involvement of KAntioxidants (Basel, Switzerland) · 2024Article
- Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Progression of type 1 diabetes is associated with high levels of soluble PD-1 in islet autoantibody-positive children.Diabetologia · 2024Article
- Regulatory TCells · 2023Review
- Adaptive and Innate Cytotoxic Effectors in Chronic Lymphocytic Leukaemia (CLL) Subjects with Stable Disease.International journal of molecular sciences · 2023Article
- Regulatory T cells targeting a pathogenic MHC class II: Insulin peptide epitope postpone spontaneous autoimmune diabetes.Frontiers in immunology · 2023Article
- Clinical and experimental treatment of type 1 diabetes.Clinical and experimental immunology · 2022Review
- Bone marrow CD3European journal of haematology · 2022Article
- Article
- T cell transgressions: Tales of T cell form and function in diverse disease states.International reviews of immunology · 2022Review
- Combined unsupervised and semi-automated supervised analysis of flow cytometry data reveals cellular fingerprint associated with newly diagnosed pediatric type 1 diabetes.Frontiers in immunology · 2022Article
- Stem Cell Transplantation in the Treatment of Type 1 Diabetes Mellitus: From Insulin Replacement to Beta-Cell Replacement.Frontiers in endocrinology · 2022Review
- The Current State of Beta-Cell-Mass PET Imaging for Diabetes Research and Therapies.Biomedicines · 2021Review
- Role of NKT Cells during Viral Infection and the Development of NKT Cell-Based Nanovaccines.Vaccines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 2 countries.
Funding
Abstract
An unresolved issue in autoimmunity is the lack of surrogate biomarkers of immunological self-tolerance for disease monitoring. Here, we show that peripheral frequency of a regulatory T cell population, characterized by the co-expression of CD3 and CD56 molecules (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.